Modality
ERT
MOA
SOS1i
Target
AHR
Pathway
Apoptosis
HCC
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
~Feb 2020
→ ~May 2021
Phase 2
~Aug 2021
→ ~Nov 2022
Phase 3
~Feb 2023
→ ~May 2024
NDA/BLA
Aug 2024
→ May 2030
NDA/BLACurrent
NCT07629200
1,899 pts·HCC
2024-08→2030-05·Terminated
1,899 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-134.1y awayPh3 Readout· HCC
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2030-05-13 · 4.1y away
HCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07629200 | NDA/BLA | HCC | Terminated | 1899 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |